Greetings from the Editorial Board of ‘Clinical Diabetology’!
There was a significant change in the Editorial Board and leadership at ‘Clinical Diabetology’ in January 2022. The new Editor-in-Chief, Dr. Viral N Shah, who is an Endocrinologist and Clinical Scientist from the University of Colorado Denver was tasked to bring ‘Clinical Diabetology’ to the international platform. Overtime, we invited experts from across the globe to form a new Editorial Board. It is a proud moment for us that within one and half years, ‘Clinical Diabetology’ has reached new heights and we are pleased to share some of our achievements with readers of the Journal.
We have noted marked increase in submissions to ‘Clinical Diabetology’ from all around the world (Fig. 1).
Despite a growing number of submissions, our timing for manuscript handling has improved significantly, with the average ‘submission — final publication’ time of less than 90 days, which was one of our first objectives. (Fig. 2).
Science is competitive and it is imperative in our current era to publish and disseminate the science as soon as possible. However, it is also important that we publish good quality science. The rejection rate for ‘Clinical Diabetology’ is now 30%; on average 1 out of 3 articles are currently rejected.
This exceptionally fast external review and quality of review would have not been possible without expert reviewers like you helping us select the best articles. Our external reviewer pool is expanding and including more international experts on reviewers’ panel. We would like you to join the growing pool of expert reviewers. At the end of every year, we acknowledge our reviewers and provide them a reviewer certificate as a token of our appreciation.
Readers of ‘Clinical Diabetology’ may have noticed that each issue has been published on time for the past 1.5 years and each issue has been standardized for structure with the goal of including an editorial, 5–6 original articles, 1–2 review articles, and 1–2 letters.
We are very serious about tackling the issue of ‘Paper Mill’ publications. A paper mill is a “profit oriented, unofficial and potentially illegal organization that produces and sells fraudulent manuscripts that seem to resemble genuine research. We are strictly enforcing authors to provide an ethical approval statement in the Methods section, clinical trial registration number, or systematic review registration if applicable. Our staff also verifies the IRB or trial registration number as a part of this rigorous approval process. Moreover, each accepted article is checked for plagiarism via i-Thenticate software.
We are excited to bring a few more changes to ‘Clinical Diabetology’. First, we have recently updated author instructions to facilitate manuscript formatting. We hope that our new and improved author instructions will make authors efficient in preparing their manuscript for ‘Clinical Diabetology’ and this may avoid initial Editorial Rejection due to improper formatting. Second, we are planning to apply for a PMC (Pubmed Central) database and we hope that this indexing will encourage more researchers to submit their research to ‘Clinical Diabetology’.
Finally, being an ESCI (Emerging Sources Citation Index) journal, ‘Clinical Diabetology’ – as announced by JCR 2023 (Journal Citation Reports) on June 28th, 2023 — has received its first Impact Factor of 0.7. This is a great start especially considering that the number of contributing self-citations was very low and the total number of citations year-to-year keeps growing.
It is an exciting time at ‘Clinical Diabetology’! We invite to join us by submitting your research contributions, be a reviewer, and help us grow. We would appreciate your suggestions and let’s make ‘Clinical Diabetology’ an international Journal together!